Core Insights - Novonesis achieved 8% organic sales growth in the first nine months of 2025 and has raised its full-year outlook to 7-8% from the previous 6-8% [1][4] - The company reported a strong adjusted EBITDA margin of 37.3%, despite facing significant currency headwinds [1][2] Sales Performance - Organic sales growth was broad-based at 8%, with a slight negative impact from exiting certain countries of approximately 1 percentage point [1][2] - The Food & Health segment saw 9% organic sales growth, while Planetary Health recorded 8% [2] - Emerging Markets outperformed with 12% organic sales growth, compared to 6% in Developed Markets [2] Financial Metrics - Adjusted EBITDA margin improved to 37.3%, up by 130 basis points, while adjusted net profit increased by 22% [2] - Net Interest-Bearing Debt (NIBD) to EBITDA ratio stood at 2.0x, with free cash flow before acquisitions reported at EUR 668.4 million [3] 2025 Outlook - The company expects organic sales growth for the full year to be between 7-8%, with mid-single-digit growth anticipated for Q4 [4] - Excluding the impact of exiting certain countries, organic sales growth is projected at 8-9% for the year [4] - The adjusted EBITDA margin is expected to be at the lower end of the 37-38% range [4]